Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Equity (2021 - 2023)

Historic Return on Equity for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to 1.35%.

  • Candel Therapeutics' Return on Equity fell 7200.0% to 1.35% in Q3 2023 from the same period last year, while for Sep 2023 it was 1.35%, marking a year-over-year decrease of 7200.0%. This contributed to the annual value of 0.63% for FY2022, which is 6400.0% up from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Return on Equity is 1.35%, which was down 7200.0% from 1.03% recorded in Q2 2023.
  • Candel Therapeutics' Return on Equity's 5-year high stood at 0.41% during Q4 2021, with a 5-year trough of 2.43% in Q3 2021.
  • In the last 3 years, Candel Therapeutics' Return on Equity had a median value of 0.71% in 2022 and averaged 0.93%.
  • As far as peak fluctuations go, Candel Therapeutics' Return on Equity skyrocketed by 18100bps in 2022, and later crashed by -7200bps in 2023.
  • Candel Therapeutics' Return on Equity (Quarter) stood at 0.41% in 2021, then plummeted by -74bps to 0.71% in 2022, then plummeted by -91bps to 1.35% in 2023.
  • Its last three reported values are 1.35% in Q3 2023, 1.03% for Q2 2023, and 0.81% during Q1 2023.